Welcome to the Enzyme Technology Alliance – We offer protein R&D from discovery to manufacturing across the entire value chain.
Under the framework of the Enzyme Technologxy Alliance the independent partners jointly tackle complex development projects spanning from in-silico catalyst discovery over AI-supported enzyme engineering to biocatalyst immobilization, DOE-based process intensification and scale-up of both enzyme production and the chemo-enzymatic process. Like interlocking pieces of a puzzle, the strengths of each member are combined not only to create a new point of contact for the biotech industry, but offer competitive solutions for both superior proteins and chemical entities.
Core expertise & USP:
Enzyme discovery using bioinformatics and modelling
Next generation enzyme evolution employingstate of the art in silico approaches and artificial intelligence
Tailored enzyme immobilization and enzymatic process development
Scale-up of chemo-enzymatic processes and enzyme production
CDMO service on industrial biocatalysis from gram to ton
Who we are and why we formed an alliance:
The journey from a protein sequence to a final biocatalytic process to deploy at scale requires broad expertise in R&D and manufacturing to enable success. The Enzyme Technology Alliance now allows start-ups and corporations globally to access the full scope of protein development to marketable (chemical) products. Founders and members of the alliance are the technologically complementary European biotech-SMEs Candidum GmbH, Aminoverse B.V., ChiralVision B.V. and Enzymicals AG comprising 50 scientific experts and more than 150 years of combined experience in managing projects ranging from enzyme discovery to facilitating cGMP enzymatic production of API’s.
Candidum generates custom enzyme solutions with an emphasis on reducing complexity and improving predictability by integrating computational design into the enzyme development process. We identify the most promising enzymes that natural evolution has to offer and engineer the synthetic potential of selected enzyme templates by means of focused libraries that are customizable towards multiple design targets in parallel. Our holistic approach enables us to quickly adapt to changes in project, process or IP requirements to de-risk R&D projects.
Aminoverse enables clients to accelerate and de-risk enzyme innovation in the early value chain from target reaction to tailored enzyme. Founded in 2020, Aminoverse’s CRO services combine enzyme wet lab expertise with in silico design boosted by its recently launched proprietary AI technologies “EnzyMAP” and “EnzyREC”. For biocatalysis, Aminoverse offers the world’s largest collections of unspecific peroxygenases and ketoglutarate-dependent oxygenases for rapid hit screening – free or 3rd party IP and scalable. Aminoverse is the go-to enzyme R&D partner for successful enzyme discovery and next generation enzyme engineering with attractive IP regulations.
For over 16 years ChiralVision has designed, developed and scaled-up hundreds of immobilized enzyme processes for all thinkable markets. Chemistry is reinvented by applying biocatalysis and enzyme immobilization to your process. Finding the right enzyme takes you only half way. Designing the production process around it and applying immobilization to allow for more extreme conditions, recycling, continuous processing and full enzyme removal takes you all the way
Enzymicals stands for tailor-made enzymes, customized chemicals and individual process solutions. The German enterprise has created a customer-oriented industrial platform for process development and piloting of chemo-biocatalytic synthetic routes for high-quality fine chemicals. Enzymicals is your experienced partner for industrial biocatalysis from gram to ton-scale with more than a decade of experience. Together with our network partners, our services can be expanded to cGMP production and bulk scale supply.
In order to ensure the flexibility and independence of all partners, the relationship between the companies is not exclusive and thus offers room for deviating requirements or individual preferences of the clients. A lead partner is available as main contact to the client and the other partners will be regarded as a subcontractor in collaborative projects. This approach has already been proven between the SMEs and offers clear competitive advantages while keeping administrative burden at a minimum, providing full control over the flow of confidential information and facilitating transparent IP transfer to the client.
MEET US! At CPhI Barcelona, October 24-26, 2023 at BOOTH CCE19
The ETA Members Aminoverse, ChiralVision and Enzymicals look forward to meeting you!